Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin

The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose c...

Source: Cardiovascular Diabetology - June 28, 2023 Category: Cardiology Authors: Pankaj Puar, Makoto Hibino, C. David Mazer, Andrew T. Yan, Arjun K. Pandey, Adrian Quan, Hwee Teoh, David A. Hess, Raj Verma, Kim A. Connelly and Subodh Verma Tags: Research Source Type: research